Browsing Interface : Welcome guest : log in
|
Browsing Interface : Welcome guest : log in |
[
Home |
Graph |
LogLearn |
Editor |
]
KB:
Language:
Formal Language:
|
| Sarilumab(sarilumab) |
| appearance as argument number 1 |
|
| (subclass Sarilumab MonoclonalAntibody) | Medicine.kif 5282-5282 | Sarilumab is a subclass of monoclonal antibody |
| (documentation Sarilumab EnglishLanguage "Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.[from Wikipedia]") | Medicine.kif 5284-5289 | Sarilumab is a subclass of monoclonal antibody |
| appearance as argument number 2 |
|
|
| (termFormat EnglishLanguage Sarilumab "sarilumab") | Medicine.kif 5290-5290 | |
| (diseaseMedicine RheumatoidArthritis Sarilumab Injecting) | Medicine.kif 5291-5291 | Rheumatoid arthritis is disease treatment sarilumab for injecting |
| (subclass Kevzara Sarilumab) | Medicine.kif 5293-5293 | Kevzara is a subclass of sarilumab |
|